Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Healthline

Does Medicare Cover Entyvio

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...
FiercePharma

In 2nd attempt, Takeda scores FDA nod for subcutaneous version of Entyvio

Nearly four years after the FDA rejected Takeda’s attempt to develop a subcutaneous formulation of blockbuster Entyvio (vedolizumab), the Japanese company has won the regulator over with its ...
Nasdaq

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
AOL

Medicare coverage for Entyvio: What to know

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...